A unique and safe way to buy gold and silver 2013 Passport To Freedom Residency Kit
Buy Gold & Silver With Bitcoins!

Friday, December 7, 2012

Gold World News Flash

Gold World News Flash


GoldSeek.com Radio Gold Nugget: Gerald Celente & Chris Waltzek

Posted: 07 Dec 2012 08:29 AM PST

GoldSeek.com Radio Gold Nugget: Gerald Celente & Chris Waltzek

Ira Epstein's Weekly Metal Report

Posted: 07 Dec 2012 08:03 AM PST

Since it became apparent that there was not going to be a compromise forthcoming soon between the President and the House of Representatives, I've been trying to figure out the impact that has on gold. I think I understand it, which is the reason for this reports "Austerity" headline.

Asian Metals Market Update

Posted: 07 Dec 2012 12:05 AM PST

Technically gold and silver seems to have formed a short term bottom after the European central bank chief indicated of more interest rate cuts next year. All the good news on US nonfarm payrolls has been factored in by the markets and if the numbers come in below street expectations then gold and silver could see another wave of rise.

“Mystery Gold Seller” Spied in Asia

Posted: 06 Dec 2012 10:00 PM PST

by Adrian Ash, Financial Sense:

Investment Banks Argue Over 2013 Outlook

The gold price traded in a narrow range around $1691 per ounce Thursday morning in London, rising slightly from yesterday's 1-month low.

Asian and European stock markets also ticked higher, as did US Treasury bonds.

Silver rallied to $32.78 per ounce after losing nearly 3% this week so far, but commodities more broadly slipped again.

"Risks to our [economic] growth outlook remain elevated," said a widely-reported gold price forecast from investment-bank Goldman Sachs on Wednesday, "especially given the uncertainty around the fiscal cliff.

Read More @ financialsense.com

Ben Davies – Gold Shorts Are Now Exposed To a Price Spike

Posted: 06 Dec 2012 09:30 PM PST

from KingWorldNews:

Today Ben Davies spoke with King World News about the shorts now being vulnerable to a price spike in gold. He also discussed surging Chinese demand and supply troubles. But first, here is what the rising star had to say about the action in gold: "I actually think we are in and around the lows now, and the market will continue to stabilize here. The other point would be that the fundamentals behind gold, in terms of mining supply, the cost of extraction, the grade degradation, this is a real issue."

Ben Davies continues @ KingWorldNews.com

ECB's Draghi Undercuts the Euro

Posted: 06 Dec 2012 09:00 PM PST

by Dan Norcini:

Over the last few weeks, the Euro has benefitted from growing concerns over the fiscal health of the US. The current grossly misnamed "fiscal cliff" talks have allowed money flows to make their way back into the common currency at the expense of the US Dollar.

That has changed in today's session. ECB President Mario Draghi's comments at a press conference have been interpretted as quite dovish by the trading community. Even though the ECB kept interested rates unchanged, the talk in the market quickly moved in response to what many feel was Draghi's leaving the door open for rate cuts in the not-too-distant future. What this means is that the interest rate environment in the Eurozone will remain negative in real terms. This is the type of scenario in which gold thrives.

Read More @ TraderDanNorcini.Blogspot.com

Is a Global Gold Supply Crunch Forming?

Posted: 06 Dec 2012 08:20 PM PST

by Jeff Clark, Casey Research:

A number of market analysts and gold-industry insiders are warning about a possible shortage of gold supply. Barrick CEO Jamie Sokalsky recently stated that since gold production is inelastic (i.e., insensitive to price changes) there will be a very limited increase in supply from gold producers, even during sharp increases in the gold price. Rick Rule, a billionaire and avid gold investor, pointed out that while we're seeing spectacular demand, a number of issues will make supply very tight in the future, especially among retailers.

The issues facing gold miners are well known: depletion of existing mines, lower grades, and fewer new discoveries – especially big and rich ones. Further, miners face increased calls for nationalization, demands from workers for higher pay or from local communities for better infrastructure, and – of course – environmental concerns. Many mining company representatives say it's getting harder to not only find large deposits but to get those deposits into production. Some estimate it now takes twice as long as to go from discovery to production vs. a decade ago.

Read More @ CaseyResearch.com

The rating agencies and America’s debt ceiling

Posted: 06 Dec 2012 07:30 PM PST

from Gold Money:

In the summer of 2011, as the United States government approached its supposed "debt ceiling", there was a raucous debate in Washington. The highly publicised (and politicised) nature of the battle captured the market's attention and cast a spotlight on American profligacy. It also clearly showed that there was no legitimate plan going forward to significantly address the government's severe debt problem.

One interesting side effect of the process was that the credit ratings agency Standard & Poor's decided to downgrade the USA's sovereign credit rating from AAA to AA+. With the US government on course to hits its new limit early next year, is another downgrade coming?

Based on commentary made by S&P at the time of the first cut, another one from them could well be possible. Below is an excerpt from S&P's statement at the time of the downgrade:

Read More @ GoldMoney.com

Issac Newton on fiat “money”

Posted: 06 Dec 2012 07:17 PM PST

Squatting on the shoulders of midgets

by Simon Black on December 6, 2012

Newton

December 6, 2012
Santiago, Chile

Isaac Newton, the father of classical mechanics and progenitor of nearly every technology we use today, was easily one of the top 10 most influential minds in all of human history…so much so that even Albert Einstein kept a picture of Newton in his study.

Newton's achievements were so momentous that when he died in 1727, he was buried with the honors normally reserved for a king. His body lay in state for four days at Westminster Abby, and his pallbearers included two dukes, three earls, and the Lord Chancellor.

Yet as accomplished as he was, Newton credited the brilliant scientists and philosophers who came before him, acknowledging that his insights would not have been remotely possible without the foundations laid by great thinkers– Archimedes, da Vinci, Descartes, etc.

In a personal letter to a colleague in 1676, Newton famously remarked "If I have seen further it is by standing on [the] shoulders of giants."*

No doubt, all great ideas flourish by expanding upon the works of others. Unfortunately, so do terrible ones. And one of the worst ideas in history that continues to play out today is the grand experiment of fiat money.

The idea is simple. Rather than allowing money to be scarce and have intrinsic value, our fiat system grants power to a tiny elite to conjure money out of thin air. Presumably, if the ones in control are smart, honest guys, then everything should be fine.

Fiat was a total failure right from the beginning. When unbacked paper currency was originally introduced in the 11th century by Emperor Renzong of the S'ung dynasty, nasty inflation quickly followed.

The Yuan dynasty later adopted the same tactic of printing paper money without restriction, and they, too, suffered severe hyperinflation.

In fact, upon visiting China from Europe, Marco Polo remarked in his writings with incredulity how '[a]ll these pieces of paper are issued with as much solemnity and authority as if they were of pure gold or silver… and indeed everybody takes them readily. . ."

For Marco Polo, this was unheard of. In the Europe of his time, the gold Florin was the major medium of exchange, not paper. And the Florin famously held its metal content at precisely 54 grains of fine gold for nearly three centuries.

It took a few hundred years, but the fiat idea eventually spread to the west. Today, fiat is the global standard; just as in Yuan China, paper is readily accepted as money, and future historians will likely look back on us the same incredulity as Marco Polo viewed the Yuan.

Nevertheless, we have our own 'brilliant scientists' championing this bad idea. We award our most esteemed prizes for intellectual achievement to men like Paul Krugman and Joseph Stiglitz who tell us that the path to prosperity is for one person to conjure trillions of dollars out of thin air… or to impose capital controls, raise taxes, or spend more money.

Like Newton, they're merely building upon the foundations laid by men who came before them. Unlike Newton, they take bad ideas and make them worse, squatting on the shoulders of [intellectual] midgets like John Maynard Keynes, whose works include such gems as:

"Can America spend its way into recovery? Why, obviously!"

"[M]oney borrowed and spent will revive the economy."

"[E]arthquakes, even wars… serve to increase wealth…"

"[To] fill old bottles with bank notes, bury them at suitable depths in disused coal mines. . . and leave it to private enterprise… to dig the notes up again… is not so different from gold mining…"

It borders on the absurd… as if it were all written as part of a satire. Yet in one of the most intellectually dishonest statements ever made, Paul Krugman recently wrote that "Keynesians have been right about everything."

This is incredibly dangerous thinking. And it's important to never forget that, despite how normal things may 'feel' on the surface, the economic engines deep below are steered by these same people who worship at the cult of bad ideas.

Commodity Technical Analysis: Gold Consolidates for Second Day

Posted: 06 Dec 2012 07:13 PM PST

courtesy of DailyFX.com December 06, 2012 06:08 PM Daily Bars Chart Prepared by Jamie Saettele, CMT Commodity Analysis: “Viewed in light of the 3 wave advance from 1672.50, the trend is lower.” Rallies should be sold and estimated resistance now comes in at 1709. The most bearish count, in which the 11/30 high completes a small 2nd wave, is valid as long as price is below 1731.52. 1685 may provide interim support. Commodity Trading Strategy: Look to short strength near 1709 with a 1732 stop. 1630/45 (measured level and 8/31 low) is the target area. LEVELS: 1646 1673 1685 1709 1723 1735...

Ross Silver on How to Find the Perfect Combo of Biotech Science and Market Savvy

Posted: 06 Dec 2012 07:13 PM PST

The Life Sciences Report: Your focus at Vista Partners is on small- and micro-cap companies where investors can potentially make big gains. Do you have a sector bias, and what sectors do you cover? Ross Silver: To identify companies we believe are compelling investment opportunities we do two things. First, we invest our own capital into the companies. Second, we write research about these particular companies and disseminate our research and monthly newsletters for free on our website. As for sector bias, we are generalists for the most part, but we tend to focus on healthcare and technology companies because we believe the majority of alpha is derived in those particular industries. A healthcare or early-stage biotech company with a $10 million ($10M), $20M or $30M market cap has the potential to become a multibillion-dollar company in a relatively short period of time—over 5–10 years, let's say. With a small-cap retailer that transformation would take a lot longer, although there ...

The Incredible Collapse of Value of Silver

Posted: 06 Dec 2012 06:30 PM PST

by Antal Fekete, SilverBearCafe.com:


What says the silver with her virgin hue?
"Who chooseth me shall get as much as he deserves."

(Shakespeare, The Merchant of Venice)

The Incredible Collapse of Value of Silver

Don't Blame Comstock!

An Address Delivered at the Conference Held at the University of Padova on November 30, 2012

"Coin Finds and Historical-Economic Processes in the Ancient World: Ten Years of Research 2002-2012″

The silver standard did not die a natural death. It was deliberately killed. A proper search for the assassins was never carried out. There was never a post-mortem. In this paper we focus on the conspiracy as it might have unfolded between the two dates: April 9, 1865 (the day General Lee of the Confederacy surrendered at Appomattox to General Grant of the Union marking the end of the War Between the States) and January 1, 1879 (Resumption Day, when payment of the victorious Union's currency, the greenback was resumed in gold specie – but not in silver).

Read More @ SilverBearCafe.com

The Silver and Gold Price Remain in a Primary Uptrend and have Another 5 - 10 Years to Rise

Posted: 06 Dec 2012 04:36 PM PST

Gold Price Close Today : 1700.30
Change : 7.90 or 0.47%

Silver Price Close Today : 33.039
Change : 0.156 or 0.47%

Gold Silver Ratio Today : 51.463
Change : -0.004 or -0.01%

Silver Gold Ratio Today : 0.01943
Change : 0.000001 or 0.01%

Platinum Price Close Today : 1599.20
Change : 16.50 or 1.04%

Palladium Price Close Today : 695.55
Change : 9.60 or 1.40%

S&P 500 : 1,413.94
Change : 4.66 or 0.33%

Dow In GOLD$ : $158.96
Change : $ (0.24) or -0.15%

Dow in GOLD oz : 7.690
Change : -0.012 or -0.15%

Dow in SILVER oz : 395.74
Change : -0.67 or -0.17%

Dow Industrial : 13,074.74
Change : 39.55 or 0.30%

US Dollar Index : 80.23
Change : 0.404 or 0.51%

The GOLD PRICE recovered $7.90 today to close Comex at $1,700.30. Silver gained 15.6 cents to end at 3303.9c.

Both the silver and GOLD PRICE today posted lows about equal to yesterday's: 3252.8 and $1,685.90. That MIGHT be a double bottom, but only if they make good that threat by rising again tomorrow.

Gold's close was cosmetically thrilling -- above $1,700 -- but technically meaningless, falling short of $1,705 resistance. I would wax more enthusiastic if gold touched first off its 200 DMA (1,665) or 150 DMA (1,662).

The SILVER PRICE continues more photogenic than gold, and is only pennies blow its 20 DMA (3311c) and 50 DMA (3310c). Again, like talking to a man without driver's license or name tag, we'd like some more substantial proof that silver won't disappoint us again. Closing above 3320 tomorrow would help, as would gold respectably above $1,705.

Then we can worry and vex ourselves about something else.

Keep thine eyes on the prize! Silver and gold remain in a primary uptrend, and have another 5 - 10 years to rise. Next rally up in both metals began in August, and you are just now witnessing the last of the correction off that rally. Whether it begins this month or next, look for another big rally, one of those 1-1/2 to two year ones.

Once again, in spite of the US dollar index rising 40.4 basis points (0.52%) and above 80 resistance, silver and gold rose. Dollar did nothing more that rise to the resistance line it had fallen through in the past two days. Next move down ought to be meaty.

Euro hit that overhead downtrend line and fell back like Vlad Dracula meeting a silver crucifix. Gold in euros had fallen to its 200 day moving average, through a bit, and today shot back above it. Should move higher -- gold, that is, not the euro.

Yen rose a little nothing today, to 121.35c/Y100. No big upside happening here any time soon.

STOCKS proved incompetent once more day to close above 13,080. Dow rose 39.55 (0.3%) to 13,074.74, while the S&P500 trailed right along beside, up 0.33% (4.66) to 1,413.94.

Stocks are stuck, but will most likely rise further into year end -- not that such a prospect induces me to own them.

Argentum et aurum comparenda sunt -- -- Gold and silver must be bought.

- Franklin Sanders, The Moneychanger
The-MoneyChanger.com
1-888-218-9226
10:00am-5:00pm CST, Monday-Friday

© 2012, The Moneychanger. May not be republished in any form, including electronically, without our express permission.

To avoid confusion, please remember that the comments above have a very short time horizon. Always invest with the primary trend. Gold's primary trend is up, targeting at least $3,130.00; silver's primary is up targeting 16:1 gold/silver ratio or $195.66; stocks' primary trend is down, targeting Dow under 2,900 and worth only one ounce of gold; US$ or US$-denominated assets, primary trend down; real estate bubble has burst, primary trend down.

WARNING AND DISCLAIMER. Be advised and warned:

Do NOT use these commentaries to trade futures contracts. I don't intend them for that or write them with that short term trading outlook. I write them for long-term investors in physical metals. Take them as entertainment, but not as a timing service for futures.

NOR do I recommend investing in gold or silver Exchange Trade Funds (ETFs). Those are NOT physical metal and I fear one day one or another may go up in smoke. Unless you can breathe smoke, stay away. Call me paranoid, but the surviving rabbit is wary of traps.

NOR do I recommend trading futures options or other leveraged paper gold and silver products. These are not for the inexperienced.

NOR do I recommend buying gold and silver on margin or with debt.

What DO I recommend? Physical gold and silver coins and bars in your own hands.

One final warning: NEVER insert a 747 Jumbo Jet up your nose. No, I don't.

Gold Pops above $1700; Silver above $33

Posted: 06 Dec 2012 04:00 PM PST

[url]http://www.traderdannorcini.blogspot.com/[/url] [url]http://www.fortwealth.com/[/url] Shorts decided to book profits today when the market appeared to have encountered some decent sized buying down near the session lows. Additionally, the upcoming payrolls report has traders uneasy and it seemed like the better part of wisdom for many was to take what money you might have had on the table and go home and watch the action from a safer vantage point. Open interest declines are telling us that traders are heading to the exits, both longs and shorts as right now uncertainty seems to be the name of the game. Tomorrow will provide us with a clue to market direction into next week as we close out the week. Gold did run down towards the very strong support level noted on the chart at $1680 before running out of sellers. A push back through the $1700 that can remain above that point will be constructive from a technical perspective as it will reinforce the $1680 - $1685 region as good...

Squatting On The Shoulders Of Midgets

Posted: 06 Dec 2012 03:45 PM PST

Authored by Simon Black of Sovereign Man blog,

Isaac Newton, the father of classical mechanics and progenitor of nearly every technology we use today, was easily one of the top 10 most influential minds in all of human history... so much so that even Albert Einstein kept a picture of Newton in his study.

Newton's achievements were so momentous that when he died in 1727, he was buried with the honors normally reserved for a king. His body lay in state for four days at Westminster Abby, and his pallbearers included two dukes, three earls, and the Lord Chancellor.

Yet as accomplished as he was, Newton credited the brilliant scientists and philosophers who came before him, acknowledging that his insights would not have been remotely possible without the foundations laid by great thinkers– Archimedes, da Vinci, Descartes, etc.

In a personal letter to a colleague in 1676, Newton famously remarked "If I have seen further it is by standing on [the] shoulders of giants."*

No doubt, all great ideas flourish by expanding upon the works of others. Unfortunately, so do terrible ones. And one of the worst ideas in history that continues to play out today is the grand experiment of fiat money.

The idea is simple. Rather than allowing money to be scarce and have intrinsic value, our fiat system grants power to a tiny elite to conjure money out of thin air. Presumably, if the ones in control are smart, honest guys, then everything should be fine.

Fiat was a total failure right from the beginning. When unbacked paper currency was originally introduced in the 11th century by Emperor Renzong of the S'ung dynasty, nasty inflation quickly followed.

The Yuan dynasty later adopted the same tactic of printing paper money without restriction, and they, too, suffered severe hyperinflation.

In fact, upon visiting China from Europe, Marco Polo remarked in his writings with incredulity how '[a]ll these pieces of paper are issued with as much solemnity and authority as if they were of pure gold or silver… and indeed everybody takes them readily. . ."

For Marco Polo, this was unheard of. In the Europe of his time, the gold Florin was the major medium of exchange, not paper. And the Florin famously held its metal content at precisely 54 grains of fine gold for nearly three centuries.

It took a few hundred years, but the fiat idea eventually spread to the west. Today, fiat is the global standard; just as in Yuan China, paper is readily accepted as money, and future historians will likely look back on us the same incredulity as Marco Polo viewed the Yuan.

Nevertheless, we have our own 'brilliant scientists' championing this bad idea. We award our most esteemed prizes for intellectual achievement to men like Paul Krugman and Joseph Stiglitz who tell us that the path to prosperity is for one person to conjure trillions of dollars out of thin air… or to impose capital controls, raise taxes, or spend more money.

Like Newton, they're merely building upon the foundations laid by men who came before them. Unlike Newton, they take bad ideas and make them worse, squatting on the shoulders of [intellectual] midgets like John Maynard Keynes, whose works include such gems as:

"Can America spend its way into recovery? Why, obviously!"

 

"[M]oney borrowed and spent will revive the economy."

 

"[E]arthquakes, even wars… serve to increase wealth…"

 

"[To] fill old bottles with bank notes, bury them at suitable depths in disused coal mines. . . and leave it to private enterprise… to dig the notes up again… is not so different from gold mining…"

It borders on the absurd… as if it were all written as part of a satire. Yet in one of the most intellectually dishonest statements ever made, Paul Krugman recently wrote that "Keynesians have been right about everything."

This is incredibly dangerous thinking. And it's important to never forget that, despite how normal things may 'feel' on the surface, the economic engines deep below are steered by these same people who worship at the cult of bad ideas.

* The 'shoulders of giants' phrase is not originally Newton's, and when he wrote it to his contemporary and rival Robert Hooke, it was in half-jest, half-humility.

It's that time again

Posted: 06 Dec 2012 03:44 PM PST


December 6, 2012

 

Mogambo Guru

 

 

                                    It's that time again

 

These are, indeed, times that try men's souls.  To such a profound revelation, some would perhaps delightedly say "Indeed, Mogambo!"   Perhaps you, too, are inclined to say "Well said, Mogambo! Thou art truly the greatest of writers, who can, with a mere fillip of prose or punctuation, turn a such simple phrase into immortal, graceful poetry, and anybody who criticizes you is an idiot and a jealous, loudmouth, know-nothing halfwit who wouldn't know true writing talent if it came up to them and took a whiz on their shoes!"

 

If so, I have to confess that I did not, alas, write it. But thanks, anyway.

 

That famous phrase is from, as it turns out, Thomas Paine, who used it in his "The American Crisis."

 

He actually wrote  Cached - SimilarYou +1'd this publicly. Undo"These are the times that try men's souls," so you can see how I vastly improved upon this Paine guy by cleverly inserting the word "indeed," brilliantly using a couple of commas, and deftly removing the "the."  

 

This, I am sorry to say, however novel and clever I hope it is, is sadly indicative of the woefully low level of personal creativity that I display these days, probably contributing to my appallingly "relaxed" attitude towards blatant, outright plagiarism.

 

In my own defense, please remember that what I admittedly lack in talent or professional ethics, I make up for with other, perhaps more endearing, qualities.

 

 I mean, who can deny my sheer, screaming paranoia?  And with that, I throw in -- for free! -- a howling, homicidal anger, and an incoherent, blubbering blood-thirst for awesome revenge against the treachery and betrayal of America by legions of greedy, smug morons for the last half century, ranging from the lowliest leftist voter thinking the government is there to "help people," up through the vast, expansive realms of "We're helping everyone, and borrowing ourselves into bankruptcy to do it" governments, and, perhaps most painful of all to see, up through the awful Supreme Courts.

 

All of these inexcusable dimwits are totally ignorant of the Constitution of the United States literally requiring that money shall be ONLY gold and silver specifically so that the money supply can't grow, thus preventing any inflation in the money supply, thus preventing the emergence of inflation in prices, and thus also preventing unsustainable, bankrupting bubbles in sectors like housing bubbles, stock market bubbles, bond market bubbles, size of government bubbles, size of debt bubbles, number of government dependents bubbles, and the entire, total tonnage of pure economic stupidity and simpleminded sophistry espoused by loathsome neo-Keynesian econometric halfwits like Alan Greenspan and Ben Bernanke and every other worthless butt-wipe who works, or ever worked, at the evil Federal Reserve, and the overwhelming proportion of the nation's colleges and universities, all of whom I blithely brand as a clot of clownish, intellectually-impoverished, poseur dimwits who see NOTHING wrong with ANY of this monetary and fiscal absurdity, when it is perfectly, blazingly, blatantly obvious that there is absolutely nothing right about it, and that is why it is a total failure and has achieved such disastrous results,  Decade after freaking decade! Dimwits all!

 

Whew! I pause to catch my breath, surprised at the raw anger pouring out of me, perhaps borne of fear that my wife will notice that I took a lousy twenty bucks from her purse when she, foolishly, was not keeping an eye on it, like I am personally to blame for her lack of responsibility and need to go to the bathroom.

 

Or perhaps I am upset about how the time is soon coming for rioting mobs of desperate people frantically flooding through the streets, their money inflated to worthlessness, ruined financially, economic zombies, looking for a handout and someone to blame for their plight, all because the evil Federal Reserve under the satanic Alan Greenspan, from 1987 to 2006, started the bank's treacherous trend of creating so incredibly much, so astonishingly much, so tragically too, too much money and credit, based on the sorry excuse of error-filled equations in worthless neo-Keynesian econometric lunacy.

 

And then these angry, desperate people, making the mistake of their lives, will think to themselves "Hey! That Irritating Mogambo Moron (IMM) was right!  If we had invested in gold, silver and oil like he said to do, we would be rich, instead of being poor and wretched!  Let's go over to his house, attack his stupid Mogambo Bunker Of Doom (MBOD), and if any of us survive the assault, we can split the gold and silver, and any leftover ammunition, we find inside!"

 

Through the periscope of the bunker I will, of course, see them coming. As they reach the perimeter that I have arbitrarily and secretly designated, I will give the klaxon a mighty, high-decibel blast, and the PA system will blare "Intruder alert! Intruder alert!", all of which has a very, very intimidating effect, as I found out the hard way when I came home one night, staggering from another alcohol-related incident, accidentally tripped the alarms and, just as accidentally, peed in my pants I was so startled and scared!

 

Well, it sure made a lasting impression on me! And on the family and neighbors, too, who came out to see what the fuss was about, and they saw me, and they laughed at me, mocking me, their insulting jeering and jabbering cutting through me like a Red Hot Knife Of Shame (RHKOS), yet they turn around the very next day and wonder why I hate them so much!  Stupid or what, huh?

 

Anyway, through the Mogambo Communication Portal (MCP), I will ask them "What do you want, or shall I startle you once again?"  They will say "We want you to give us some dry pants and some clean underwear; we peed all over ourselves here! And we want all your gold and silver, too, so that we can buy ourselves some food and get some nice clothes that haven't been slept in or peed in!"

 

I, of course, will say "No. But as true Democrats, you got the attitude down perfectly!"

 

After a lot of flustering and blustering, stumbling about in their confused stupidity, I will ask "Are you the same people who think that an idiocy like 'government deficit-spending to make up for lack of private spending because everybody is bankrupted under a massive load of debts, which is why they stopped spending' could possibly, possibly, ever in a million jillion years, work, when it never, ever has? Are you they? Is you them? Which or neither? Answer me! Now!"

 

Of course they will say "What? Uh, no, we are not those people, we don't think!"  I will laugh at them, and reply with a twinkle of amused merriment in my voice, "Are you telling me that you instantly, intuitively understand, like normal people with even half a brain, that a constant freaking flood of new, government money disastrously distorts an already distorted, government-centric economy, making a normal recovery totally, completely impossible, as seemingly proved --proved! -- because nobody has ever, EVER heard of a case, in all these thousands of years of history, of robust private demand, despite cancerous over-indebtedness (and impending pandemic bankruptcy) somehow, perhaps magically, growing to replace the artificial demand created with massive government deficit-spending of new fiat money?"

 

Having accumulated a lot of experience over the years, educating a lot of people about the inflationary horrors of allowing the Federal Reserve to create so much excess money and credit, and how you would have to be an idiot not to be buying gold and silver, I recognize that this is when the average person says "Huh? What? I don't understand!", as does, obviously, Ben Bernanke.

 

Don't believe me? Then find out for yourself! Call the Federal Reserve in Washington, D.C., and when they answer the phone, say "I want to ask that big butthead Ben Bernanke if he has ever heard of a case of robust private demand, despite over-indebtedness, replacing the artificial demand of massive government deficit-spending?  Now, put him on the line, and make it snappy, will ya? I ain't got all day!"

 

Go ahead! Call!  I'm betting that, like when I called and asked them this same question, they put you on hold and never picked up the call, or you were mysteriously disconnected when you called them back, over and over, getting more angry each time to helpfully let their Customer Service Department know how angry I am about Bernanke ducking my calls, probably because Bernanke DOES think this stupid crap!  Thus, it's proved, I tells ya! Proved! If he's innocent, why doesn't he come forward and deny it?

 

And that interesting-yet-terrifying tidbit of news is just another teensy, tiny clue to buy gold, silver and oil. All the other zillions of wonderful reasons to buy gold, silver and oil have 4,500 years of history backing them up.

 

And with evidence like that, against the foolish thinking of a guy who won't even answer the phone, what can one say except "Whee! This investing stuff is easy!"?

 

Can Gold Keep Its Luster in 2013?

Posted: 06 Dec 2012 03:02 PM PST

Gold took a double hit recently based partly on a news item from the rumor mill that a large fund in Asia was selling to "run the stops." Read More...

ECB mulls negative rates as Europe's economic crisis deepens

Posted: 06 Dec 2012 03:01 PM PST

December 06, 2012 11:42 AM - The European Central Bank has slashed its eurozone growth forecasts and warned that recession will drag on into the middle of next year, sending the euro plunging below €1.30 to the dollar. Read the full article at the Telegraph......

Gold Eagle sale up 150% since QE3 announcement

Posted: 06 Dec 2012 02:49 PM PST

DITCHING BEFORE THE FISCAL CLIFF By Peter Schiff | Euro Pacific Precious Metals - Turn on the TV and this is what you'll hear: The US budget is heading for a fiscal cliff. If a deal isn't reaching in Congress by the end of this year, a combination of automatic tax hikes and budget cuts will [...]

This posting includes an audio/video/photo media file: Download Now

Kaiser - Bracing for the extinction of 500 juniors or an entire institution?

Posted: 06 Dec 2012 02:33 PM PST

John Kaiser of Kaiser Research Online writes:  "During my travels the past couple months I have been repeatedly surprised by declarations from others that about 500 Canadian listed resource juniors will disappear within the next year unless there is a remarkable turnaround for the resource sector in 2013. These numbers have their origin in my May 23, 2012 Kaiser Blog post Staving off Mass Extinction with the Big Anomaly which provided the grim statistics on which this now widely circulated warning is based. Since then the situation has worsened, as is evident in the figures as of November 30, 2012 which active KRO members can see updated on a regular basis in KRO Key Charts.

  20121206Kaiser

More... 

Kaiser Research Online tracks all companies listed on the TSX and TSXV who appear to be involved with resource sector exploration, development or mining, as well as a handful of former resource juniors which have shifted their focus to energy or other arenas. We do not track the capital pools until they have made a qualifying transaction involving the resource sector, but we do track resource juniors that have abandoned their projects, reorganized, and are shells looking for a new focus. Currently we have 1,803 companies that are trading. The Working Capital Distribution chart above shows the percentage trading in each of the 12 price categories, the median working capital for each price range, and the average working capital. It also shows separately compiled figures whose particulars KRO members can peruse using our KRO Search Engine or by clicking the links in the table below.

To read the entire article and view several excellent charts follow the link below:

http://www.kaiserbottomfish.com/s/KaiserBlog.asp?ReportID=559842

 

The Answers To Today's Most Common Questions

Posted: 06 Dec 2012 02:32 PM PST

My Dear Extended Family,

This should serve as an answer to more than 300 emails:

1.   There is no top in place for the gold price. Absolutely none. 2.   This reaction is an operation using the MSM multitude of reports on the Fiscal Cliff sure to occur in order to scream unopposed deflation (wrong).

Continue reading The Answers To Today's Most Common Questions

Ben Davies - Gold Shorts Are Now Exposed To a Price Spike

Posted: 06 Dec 2012 02:26 PM PST

Today Ben Davies spoke with King World News about the shorts now being vulnerable to a price spike in gold. He also discussed surging Chinese demand and supply troubles. But first, here is what the rising star had to say about the action in gold: "I actually think we are in and around the lows now, and the market will continue to stabilize here. The other point would be that the fundamentals behind gold, in terms of mining supply, the cost of extraction, the grade degradation, this is a real issue."

This posting includes an audio/video/photo media file: Download Now

167% in Six Months – Tech Speculation Lessons

Posted: 06 Dec 2012 02:14 PM PST

Synopsis: 

What a revolutionary pharmaceutical company teaches us about technology investing.


We are not ones for bragging about our accomplishments. Whether you believe in such mystical forces as karma or not, it's generally a good rule that those who take too much credit for their successes are soon rewarded with a streak of the opposite, just to keep them humble. However, it is just as important to take stock in your achievements as it is your failures, if you are going to learn and grow as an investor (or in any pursuit). As such, this week I want to introduce you to the story of a company that we recommended to our investment advisory subscribers back in April 2012. It's since gone on to gain significantly. The stock rose 297% from our initial recommendation to the day the "sell" call was made. What's important about this small company is why it made our investment list to begin with, and what its characteristics can tell us about successful speculation in the arena of up-and-coming technology companies.

Sincerely,


Alex Daley
Chief Technology Investment Strategist
Casey Research


Anatomy of Great Technology Investment

By Alex Daley, Chief Technology Investment Strategist

Traditional cancer treatment options are little more than a crude mix of "slash, burn, and poison" – that is surgery, radiation, and chemotherapy. There are radical new treatments in labs and trials all over the world that promise to throw out this trifecta; no other disease has received more of the research interest and funding that have defined modern biotechnology over the past three decades.

I'm not going to tell you about any of those here. Sure, many of them will be wildly successful and make many investors fabulously wealthy over the next few decades. But most will fail. And those that don't will take a long time to turn a profit for investors.

Yet, there is one small company whose unique twist on cancer treatment is proving to be a major upgrade. We profiled this company in a recent edition of Casey Extraordinary Technology, and it turned in a gain of over 167% for subscribers in just six months' time. It may yet make billions more still for investors.

You see, in recent years chemotherapy has become the core treatment for most cancerous malignancies. And while these toxic cocktails of chemicals have proven effective at destroying cancerous cells, they also have one problem. A big one.

Chemo, being essentially a poison, doesn't just attack cancerous cells – it attacks a broad range of healthy cells too. As a result, the treatment can sometimes be as harmful as the cancer itself in the short run. The side effects are awful, and its use can quickly erode patients' health. Some have even described chemo as a "cure that's worse than the disease."

This sad state of affairs for the world's second most-prevalent chronic disease is why the cancer-research arena has been exploding over the past few years with the goal of developing more targeted, less-toxic therapies – in other words, to do a better job killing cancer cells while leaving healthy cells alone.

That's exactly what Lawrenceville, New Jersey-based Celsion Corp. (CLSN) has the technology to do. And chances are the company is on to one of the biggest cancer-treatment breakthroughs in decades.

How It Works

Our story starts with liposomes. These nanosized artificial vesicles are made from the same material as our cell membranes – natural phospholipids, i.e., a version of the chemicals that make up everything from fat to earwax, and cholesterol.

Not long after their discovery in the 1960s, scientists began experimenting with liposomes as a means of encapsulating drugs, especially cancer drugs. Why? Something called the "enhanced permeability and retention" (EPR) effect. This is a property of certain sizes of molecules – for example, liposomes, nanoparticles, and macromolecular drugs – which tend to accumulate in tumor tissue much more than they do in normal tissues. It's a useful feature for a cancer drug.

Thus, they offer a potential way to combat the two biggest drawbacks of traditional chemotherapeutics: systemic toxicity and low bioavailability at the tumor site. In other words, the drugs now employed are themselves are toxic to normal cells, and they tend to get largely used up before they even reach the tumor site.

Early attempts to encapsulate drugs inside liposomes did an okay job of dealing with the toxicity issue, but bioavailability at the tumor site was still limited. Our immune system saw to that. Just like virtually anything else artificial we put into our bodies, traditional liposomes were seen as invaders. Thus, they were rapidly cleared by the mononuclear phagocyte system, the part of the immune system centered around the spleen (yes, we do use it) that destroys viruses, fungi, and other foreign invaders.

However, a breakthrough arrived when scientists came up with a new way to sneak these artificial compounds into the body undetected by our defenses. The process gave us what are call "PEGylated" liposomes, with a covalent attachment of polyethylene glycol polymer chains. The effect of attaching these little plastic chains to the end of the liposome was to create a "stealth" liposome-encapsulated drug that was hardly noticed by the system.

Problem solved, right? Well, not exactly. A lot of hard work went into getting drugs into liposomes to reduce toxicity, then a bunch more into stopping our immune system from kicking in. But there was still yet another problem. The drug-release rates of these stealth liposomes were generally so low that tumor cells barely got a dose. Scientist had made them so stealthy that they even skated right by cancer cells, usually failing to kill off the tumors.

After decades of experimenting with liposome-encapsulated cancer drugs, scientists still had not been able to safely deliver therapeutic concentrations of the chemotherapy drugs to all tumor cells.

They had to devise a way to induce drug release when and where it would be more effective.

The next big idea came in more recent years, as scientists devised temperature-sensitive liposomes. Heat them and they pop, releasing the drugs just when you need them to. From stealth to non-stealth in a matter of seconds, and right on target.

Fortunately, they were able to make it work, but unfortunately, not at temperatures that didn't essentially cook patients from the inside – sort of defeating the purpose of keeping the chemo at bay to reduce collateral damage. They failed to perform at tolerable levels of heat or time. Fifteen minutes of baking and still only 40% or so of the drug was released, and it took temperatures up to 112° Fahrenheit. It might not sound like much, but it was enough to be intensely painful and damaging as well.

That's where Celsion came in. It's designed and developed a novel form of these temperature-sensitive chemo sacks – the first of their kind to work effectively and safely – otherwise known as a lysolipid thermally sensitive liposome (LTSL).

Celsion's liposomes are engineered to release their contents between 39-42° C, or 102.2-107.6° F (thus, another translation of LTSL has become "low-temperature sensitive liposome"). And they release the contents at an extremely fast rate, to boot.

A Better Way to Use Chemo

These unique properties of Celsion's LTSL technology make it vastly superior to previous liposome technology for a number of reasons.

  • For starters, the temperature range is much more tolerable to patients and won't injure normal tissue.
  • Second, the temperature range takes advantage of the natural effect mild hyperthermia has on tumor vasculature. Numerous studies have shown that temperatures between 39-43° C increase blood flow and vascular permeability (or leakiness) of a tumor, which is ideal for drug delivery since the cancer-killing chemicals have easy access to all areas of the tumor. These effects are not seen at temperatures below this threshold, and temperatures above it tend to result in hemorrhage, which may reduce or cease blood flow, hampering drug delivery. It's the Goldilocks Effect: The in-between range is perfect.
  • Third, Celsion's LTSL technology promotes an accelerated release of the drug when and where it will be most effective. That allows for direct targeting of organ-specific tumors.

Celsion's LTSL technology has shown that it's capable of delivering drugs to the tumor site at concentrations up to 30 times greater than those achievable with chemotherapeutics alone, and three to five times greater than those of more traditional liposome-encapsulated drug-delivery systems.

The company's first drug under development is ThermoDox, which uses its breakthrough LTSL technology to encapsulate doxorubicin, a widely used chemotherapeutic agent that is already approved to treat a wide range of cancers.

Currently, ThermoDox is undergoing a pivotal Phase III global clinical trial – denoted the "HEAT study" – for the treatment of primary liver cancer (hepatocellular carcinoma, or HCC), in combination with radiofrequency ablation (RFA).

RFA uses high-frequency radio waves to generate a high temperature that is applied with a probe placed directly in the tumor, which by itself kills tumor cells in the immediate vicinity of the probe. Cells on the outer margins of larger tumors may survive, however, because temperatures in the surrounding area are not high enough to destroy them. But the temperatures are high enough to activate Celsion's LTSL technology. Thus, the heat from the radio-frequency device thermally activates the liposomes in ThermoDox in and around the periphery of the tumor, releasing the encapsulated doxorubicin to kill remaining viable cancer cells throughout the region, all the way to the tumor margin.

ThermoDox is also undergoing a Phase I/II clinical trial for the treatment of recurrent chest wall (RCW) breast cancer (known as the "DIGNITY study"), and a Phase II clinical trial for the treatment of colorectal liver metastases (the "ABLATE study"). But most of the drug's (and hence the company's) value is tied up in the HEAT study.

The HEAT trial is a pivotal 700-patient global Phase III study being conducted at 79 clinical sites under a special protocol assessment (SPA) agreement with the FDA. The FDA has designated the HEAT study as a fast-track development program, which provides for expedited regulatory review; and it has granted orphan-drug status to ThermoDox for the treatment of HCC, providing seven years of market exclusivity following FDA approval. Furthermore, other major regulatory agencies, including the European Medicines Agency (EMA) and China's equivalent, have all agreed to use the results of the HEAT study as an acceptable basis to approve ThermoDox.

The primary endpoint for the HEAT study is progression-free survival – living longer with no cancer growth. There's a secondary confirmatory endpoint of overall survival, too. Both the oncological and investing community are eagerly awaiting the results, which are due any day now.

So then, why are we on the sidelines now, right when the big news is due to hit? That all goes back to why Celsion was such a good investment to begin with, and what it can tell us about finding other big wins in the technology stock market.

A Winner in the Making

When we're looking for a strong pick in the biotechnology, pharmaceuticals, and medical devices fields – once we have established the quality of the technology itself and ensured it will likely work as expected – there is a simple set of tests we apply to ensure that we've found a stock that can deliver significant, near-term upside. The most critical of these are:

  • The technology must provide a distinct competitive advantage over the current standard of care and be superior to any competitors' effort that will come to market before or shortly after our subject's does. In other words, it must improve outcomes, by improving patients' length or quality of life (i.e., a cure for a disease, or a maintenance medication with fewer side effects), or lower costs while maintaining quality of care (i.e., a generic drug). A therapy that does both is all the better.
  • The market must be measurable and addressable. There must be some way to say specifically how many patients would benefit from a therapy, and to ensure that those patients have providers caring for them that would make efficient distribution of the therapy possible. For instance, a successful treatment for Parkinson's disease might be applicable to hundreds of thousands of patients, with little competition from other treatments, whereas a treatment for Von Hippel-Lindau (VHL) might only reach hundreds. If the goal is to recover years of research investment and profit above and beyond that, then market size matters, as do current and future competitors that might limit your reach within a treatment area.
  • Payers should be easily convinced to cover the new therapy at profitable rates. In the modern world of health care, failure of a treatment to garner coverage from government medical programs like Medicare and the UK Health Service, and private insurance companies (which generally cooperate closely to decide how to classify and whether to cover a treatment) is usually a game-ender. Payers have a responsibility not just to patients but to their shareholders or taxpayers to stay financially solvent. This means that if a therapy does not provide a compelling cost/benefit ratio, then it won't be covered. For instance, if you release a new painkiller that is only as effective as Tylenol and costs $1,000 per dose, you're obviously not going to see support.
  • There must a clear path to market in the short term, or another catalyst to propel the stock upward. An investment in a great technology does not always make for a great investment. You have to consider the quality of the management team and structure of the company, including its ability to pay the bills and get to market without defaulting or diluting you out of your positions. And of course, time. The biggest and most frequent mistake investors make in technology is assuming that it is smooth and short sailing from concept to market. Reality is much harsher than that, and in biotechnology and pharmaceuticals in particular – with a tough regulatory gamut to run – the timeline to take a new technology to market can be anywhere from a decade to thirty, forty, or even fifty years.

Liposomes are a perfect example of that. Twenty years ago, I probably could have told you a story about a technology that was very similar to what was laid out above. It would be compelling and enticing to investors of all stripes – a breakthrough technology with the promise to revolutionize cancer care by making chemo less toxic and more effective at the same time. Yet had you invested in that promise alone, chances are you'd be completely wiped out by now, or maybe – just maybe – still waiting for a return.

That is why we invest in proof, not promises. So, how does Celsion stack up against our four main proof points?

Time to market: When we first recommended Celsion, it was in Phase III pivotal trials. This is the last major stage of human testing usually required before a company can submit an FDA New Drug Application and apply to market the product.

The process of bringing a drug to market, even once a specific compound has been identified and proven to work in vitro (in the lab), is perilous. Many things can go wrong along the way. If you look at investing in a company whose drugs are just entering Phase I clinical trials, for instance, it is still unclear if the therapy is effective in vivo (in the human body). This is a critical stumbling block for many companies, whose promising compounds immediately prove less effective or more dangerous than testing suggested. Even if Phase I goes well, it can take up to a decade and sometimes longer to get from there to market with a drug. And then, even Phase II trials often leave treatments five or more years from market – though there are exceptions in cases where a therapy is proven very effective or a disease has so few treatment options available. But shortcuts are rare, and investors have to consider the time and expense (which leads to fundraising and ultimately dilutes your return) of getting from A to Z.

In this regard, Celsion made a uniquely great investment. When we first recommended the company, it was in the midst of a pivotal Phase III trial and looked to be about a year or so away from its first commercialization. (Though, speaking to the length of these trials, this one had been started back in 2008.)

With many of the most high-profile companies in the industry – those working on vogue treatment areas and conditions, like hepatitis C treatments of late – when they get this close to market, the large banks bid up stocks to high levels, content to squeeze just a few percentage points out at the end. They have to be conservative, since they're investing large amounts of other people's money. However, biotechnology is such a fragmented space with far more companies than Wall Street can possibly cover in depth, that coming across a gem like Celsion late in the game with a potentially big win is not as uncommon as you'd think. The "efficient market" hypothesis fails to account for the fact that no one can know everything, including every stock. And Celsion had gone all but unnoticed for some time.

Payer acceptability: Celsion has the benefit of developing a 2.0-style product, an improvement over something that already exists. RFA is already in relatively widespread use and has proven effective enough that most every insurance and benefits provider will cover it. Even the early generations of LTSL, while not quite as safe or effective as desired, were enough of a benefit to gather pretty solid support from payers.

Celsion, through its clinical trial process, has proven its unique blend is safer, better tolerated by patients, and much more effective than its predecessors. Thus, payer support at a reasonable price is a pretty sure bet.

Market size: When we originally recommended Celsion, we stated that the company was sitting on a multibillion-dollar opportunity. And we stand by that statement. However, just because something is eventually worth that amount does not mean it's bankable today as a short-term investment. So we try to keep our analysis narrowly focused on what can be directly counted on and measured. In Celsion's case, that's the Phase III treatment, Thermodox, and the one area in which it is being studied: primary liver cancer (HCC). Even just in this narrow band, however, we see the market opportunity for Celsion as in excess of $1 billion.

HCC is one of the most deadly forms of cancer. It currently ranks as the fifth most-common solid tumor cancer, and it's quickly moving up. With the fastest rate of growth among all cancer types, HCC projects to be the most prevalent form of cancer by 2020. The incidence of primary liver cancer is nearly 30,000 cases per year in the US, and approximately 40,000 cases per year in Europe. But the situation worldwide is far worse, with HCC growing at approximately 750,000 cases per year, due to the high prevalence of hepatitis B and C in developing countries.

If caught early, the standard first-line treatment for primary liver cancer is surgical resection of the tumor. Early-stage liver cancer generally has few symptoms, however, so when the disease is finally detected, the tumor is usually too large for surgery. Thus, at least 80% of patients are ineligible for surgery or transplantation by the time they are diagnosed. And there are few nonsurgical therapeutic treatment options available, as radiation and chemotherapy are largely ineffective.

RFA has emerged as the standard of care for non-resectable liver tumors, but it has limitations. The treatment becomes less effective for larger tumors, as local recurrence rates after RFA directly correlate to the size of the tumor. (As noted earlier, RFA often fails at the margins.) ThermoDox promises the ability to reduce the recurrence rate in HCC patients when used in combination with RFA. If it proves itself in Phase III, there's no doubt the drug will be broadly adopted throughout the world once it is approved.

A quick look at the numbers: According to the most recent data from the National Cancer Institute, the incidence rates of HCC per 100,000 people in the three major markets are 4 in the US, 5 in Europe, and approximately 27 in China. Based on these incidence rates, the total addressable market in these three regions (which we will conservatively assume to be the total addressable worldwide population for the time being) is approximately 400,000 (12,000 in the US, 40,000 in Europe, and 351,000 in China).

Assuming that 50% of HCC patients are eligible for nonsurgical invasive therapy such as RFA, approximately 200,000 patients worldwide would be eligible for ThermoDox. Further assuming an annual cost of treatment for ThermoDox of $20,000 in the US, $15,000 in Europe, and $5,000 in China, in line with similar treatments of the same variety, we estimate that the market potential of ThermoDox could be up to $1.3 billion. Not to mention the countless thousands of lives saved. (And that's before the rest of the developing world comes online.)

Of course, this is an estimate of ThermoDox's potential assuming 100% market penetration – something that simply never happens. While we expect ThermoDox in combination with RFA to become the standard of care for primary liver cancer, a more reasonable expectation for maximum market penetration after a six-year ramp-up to peak sales (from an expected approval in 2013) is probably 40%.

Improving outcomes or lowering costs: This is exactly what the Phase III trial was intended to prove: efficacy beyond a shadow of a doubt. Given preliminary data and earlier trial results, it was already a pretty sure thing, so in our model, we assumed about a 70% chance of success (to be on the conservative side, as always – it's better to be right by a mile than to miss by an inch).

Once we incorporate that probability of success into our model, we come to a probability-weighted peak sales figure in 2019 of approximately $365,000,000 annually.

The average-price-to-sales ratio among the big players in biotech these days is about 5. If we apply a sales multiple of 3 (i.e., just 60% of the average) to Celsion's probability-weighted peak sales for ThermoDox in 2019, we come up with a value for the company of nearly $1.1 billion, which would equate to about $33 per share if it did not issue any new stock between now and then – that's more than 17 times where the stock was trading when we recommended a buy.

And remember, these numbers are only for ThermoDox under the HCC indication.

Our Move to the Sidelines

With final data from the current Phase III pivotal trial due expected to come in within the next few weeks, Celsion's stock has ballooned in value from the $2 range to $7.50 or so in the past few weeks. Now, that's a far cry from the $33 price we mentioned above, but remember, that's a target for 2019. And it doesn't allow for a whole range of things that could go wrong.

Chief among those concerns is that the Phase III data come in more poorly than expected. Even just a small variance in efficacy or a simple question about safety can knock a few hundred million dollars off those sales figures. Or it can push trials back a year or two, delaying returns and sending short-term-minded investors, like those who have recently bid up CLSN shares, retreating to the hills for the time being.

Further downfield there is sure to be competition as well, and of course we may get those miraculous chemo-free treatments mentioned up front.

In short, we don't have a crystal ball and can't tell you what the world will look like in 2019. If you believe yours is clear, ask yourself if you thought touchscreen phones and tablets would outsell traditional computers by 3 to 1 globally in 2012. If not, you might want to give the crystal a polish.

To be clear, the value of Celsion in the near term hinges on a binary event – the results of the ongoing HEAT trial. We are of the opinion that CLSN represents one of the best opportunities we've come across since we started this letter, and that the probability of a successful trial is high. Nevertheless, there is substantial down side if the trial is unsuccessful. And it could take years to recover, if ever, on news of a delay from any concerns raised.

We'd already advised subscribers to take a free ride early on in our coverage of the stock, taking all of the original investment risk away. However, even with that protection, the short-term potential is still more heavily weighted to the down side. Thus, we booked our profits and stepped to the sidelines on this one.

Celsion continues to be a model, even at today's prices, for a great biotech investment with significant upside potential. But we're content to wait for the market to hand us another, similar opportunity.

The pages of Casey Extraordinary Technology are filled with investments just like Celsion – up-and-coming technology companies the market has yet to discover. Subscribe today and save 25% off the regular price, as always backed by our unconditional money-back guarantee.


Bits & Bytes

More 3D-Printer Magic (Gizmag)

Last week, we noted some of the cool things people are doing with 3D printers. But it's hard to keep up. The tech is blasting ahead so fast that this week we couldn't resist adding another. Researchers at the University of Warwick, already known for its cutting-edge tech research, have created a cheap, plastic composite that can be used even with low-end 3D printers to produce custom-made electronic devices. The potential here is staggering.

Tablets – Hotter than We Thought (Computerworld)

Global market-research company IDC has revised its estimate for sales of tablets for 2012 upward by 4.5%, to 122.3 million units. Apple is expected to lose market share to surging Android-based devices.

Whose Internet Is It? (GamePolitics)

Well, the US Congress appears to think it's the people's. Other countries disagree, and have been trying to wrest control of the 'Net from our hands for a while now. Many want the UN in charge. But this week, the House unanimously passed a Senate resolution calling on the US government to officially oppose any transfer of Net control to the UN. We'd guess this battle is far from over, though.

Tattoo You? (

Gold Seeker Closing Report: Gold and Silver End Slightly Higher

Posted: 06 Dec 2012 02:11 PM PST

Gold dropped $7.56 to $1686.04 at about 8:45AM EST, but it then jumped to as high as $1703.00 in late morning trade and ended with a gain of 0.26%. Silver surged to as high as $33.259 and ended with a gain of 0.4%.

Gold Daily and Silver Weekly Charts

Posted: 06 Dec 2012 02:08 PM PST

This posting includes an audio/video/photo media file: Download Now

Gold & Silver Regain $1700 & $33 on 10 Ton Physical Gold Order

Posted: 06 Dec 2012 01:36 PM PST

After being treated to standard COMEX open waterfalls that saw gold smashed as low as $1684 and silver under $32.50 on the open, both metals made a vertical move to the upside around 10am EST. Gold cleared $1700 trading as … Continue reading

Why did Central Banks Stop Selling Gold?

Posted: 06 Dec 2012 12:59 PM PST

In 2009 the signatories of the Central Bank gold Agreement effectively stopped selling gold. This was just after signing the third Central Bank Gold Agreement which lasts until September 26th 2014. Why? In 1999, the first of such agreements was signed by the U.K. and was called the Washington Agreement. It received the tacit blessing of the U.S.A. and Japan. This was followed by the signing of the Central Bank Gold Agreement, which ran from 27th September 2004 to the 26th September 2009. Ostensibly to accommodate the I.M.F.'s sale of 403 tonnes of gold on their own books, a third Central Bank Gold Agreement was signed to run from the 27th September 2009 to the 26th September 2014. Apart from the up-to 7 tonnes year of gold sales by Germany's central bank for the minting of gold coins, there have been virtually no sales of gold from the original signatories of their gold. In fact the previously announced sales (going back to the turn of the century) have not been fulfilled completely, even now. Once the I.M.F. completed their sales of gold, the absence of the developed world's central banks from the sale side of gold spoke volumes! How?

Regarding Gold: Follow The Money

Posted: 06 Dec 2012 12:51 PM PST

Before I address my topic du jour, I wanted to follow-up quickly on my post about the weakening economy earlier this week.  Gallup released a report that was picked up by Zerohedge which showed that unemployment mysteriously jumped higher than previously thought after the election.  You can read about it here:  LINK

Of course, Hurricane Sandy will be blamed for this, but I would suspect that Gallup knows a little more about constructing statistical studies than to make that sampling error.  More likely is lackluster holiday hiring and the release of temporary Government workers hired to help out with the election.  As for the likelihood that holiday employment was weaker than usual, it turns out that not only were Black Friday sales less than forecast, but post-Black Friday sales actually dropped over 3%:  LINK

The reader is free to draw his own conclusions, but it appears as if the data coming in now supports my thesis on the economy.

To transition this into my title topic, there is no question in my mind that the Fed is going to expand its newly-minted QE3 program.  This has been well-telegraphed, but I believe what is ultimately implemented over the next 6 months will exceed expectations, as printing money is the time-honored strategy of attempting to prevent economic depression AND to finance Government spending.

The best way to take advantage of this imminent further devaluation of the dollar is to move as much of your investable funds into physical gold and silver as you can.  Also, you can create rate of return leverage with this by investing in mining stocks (which are egregiously cheap right now).  To implement this strategy, you would be piggy-backing an investor class with the best look at "inside" information regarding the issues of money printing and economic health:  the world's Central Banks.   As chronicled by this report, Central Banks globally have purchased a record amount of over 500 tonnes of gold during 2012:  LINK

To put this in perspective, the world's annual production of gold is around 2500 tonnes, give or take a few tonnes.  This output, despite the rise in China's gold mining production, is in decline - some would say serious decline.  So if Central Banks are buying at least 20% of annual production (it is thought that China is actually buying a lot more gold than they care to report), and likely will increase that off-take in 2013, and if every other source of demand just stays constant, there's only one way the price of gold can go.  There will be plenty of other factors that will drive the price higher, but this is just the sheer supply/demand dynamic.

Given that this is the case, you have to ask yourself why the Central Banks are now hoarding gold.  To me the answer is obvious:   the entities that are in control of the money supply are taking advantage of this powerful position by buying the one asset, in advance, that will rise in value as the supply of printed money rises.  And that would only occur if they intend to print a lot more of it.

Please note that, as always, I advise against using paper ETFs in lieu of buying real physical gold.  Although beyond the scope of this commentary, ETFs are not the same thing as owning real gold for many reasons.  I plan on updating my research report on GLD sometll post it here when that happens.

Gold: The Hidden Dangers?

Posted: 06 Dec 2012 12:40 PM PST

Courtesy of Dr. Paul Price : Extensive money printing (QE programs) have had many traders stocking up on Gold via ETFs, ETNs, physical coins & bars and through shares of precious metal mining companies. This urge to own hard assets in a soft money environment makes sense on an intuitive basis.

Holiday Mirth, Economic Myth

Posted: 06 Dec 2012 12:17 PM PST

December 6, 2012 [LIST] [*]Holiday shopping drives economic growth? Bah, humbug... Time for some Yuletide cheer, 5 style! [*]Gold mired below $1,700... but Guenthner says there's another level to watch that's more important [*]Cash from trash, and other investable insights Chris Mayer is bringing to the Rancho Santana Sessions [*]Home sweet home, until the bulldozer arrives: Cautionary tales from Jersey to Bordeaux [*]"Fiscal cliff" vs. "austerity measures"... taxing political contributions... and other reader musings [/LIST] "Commerce and religion and patriotism are all part of what we have come to know as the holidays," opines Leigh Eric Schmidt, a humanities professor at Washington University in St. Louis. "Consumption during the holiday season has come to have a kind of patriotic quality in the United States," he tells The New York Times. And it didn't start with George W. Bush -- who, as it turns out, never did tell Ame...

No comments:

Post a Comment